The C allele of ATM rs11212617 does not associate with metformin response in the diabetes prevention program

Jose C. Florez, Elizabeth Barrett-Connor, Kathleen A. Jablonski, William C. Knowler, Andrew Taylor, Alan R. Shuldiner, Kieren Mather, Toni I. Pollin, Edward Horton, Neil H. White

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Abstract

OBJECTIVE - The C allele at the rs11212617 polymorphism in the ataxia-telangiectasia-mutated (ATM) gene has been associated with greater clinical response to metformin in people with type 2 diabetes. We tested whether this variant modified the effect of metformin in the Diabetes Prevention Program (DPP), in which metformin reduced diabetes incidence by 31% in volunteers with impaired glucose tolerance. RESEARCH DESIGN AND METHODS - We genotyped rs11212617 in 2,994 DPP participants and analyzed its effects on diabetes incidence and related traits. RESULTS - Contrary to expectations, C carriers enjoyed no preventive advantage on metformin; their hazard ratio, comparedwith A carriers,was 1.17 ([95% CI 0.96-1.42], P = 0.13) under metformin. There were no significant differences by genotype in metformin's effects on insulin sensitivity, fasting glucose, glycated hemoglobin, or disposition index. CONCLUSIONS - The reported association of rs11212617 with metformin response was not confirmed for diabetes prevention or for effects on relevant physiologic parameters in the DPP.

Original languageEnglish
Pages (from-to)1864-1867
Number of pages4
JournalDiabetes care
Volume35
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Dive into the research topics of 'The C allele of ATM rs11212617 does not associate with metformin response in the diabetes prevention program'. Together they form a unique fingerprint.

Cite this